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Enteroaggregative Escherichia coli (EAEC) causes acute and persistent diarrhea world-
wide. Still, the involvement of host factors in EAEC infections is unresolved. Binding 
of recognition molecules from the lectin pathway of complement to EAEC strains 
have been observed, but the importance is not known. Our aim was to uncover the 
involvement of these molecules in innate complement dependent immune protection 
toward EAEC. Binding of mannose-binding lectin, ficolin-1, -2, and -3 to four prototypic 
EAEC strains, and ficolin-2 binding to 56 clinical EAEC isolates were screened by a 
consumption-based ELISA method. Flow cytometry was used to determine deposition 
of C4b, C3b, and the bactericidal C5b-9 membrane attack complex (MAC) on the bac-
teria in combination with different complement inhibitors. In addition, the direct serum 
bactericidal effect was assessed. Screening of the prototypic EAEC strains revealed 
that ficolin-2 was the major binder among the lectin pathway recognition molecules. 
However, among the clinical EAEC isolates only a restricted number (n = 5) of the iso-
lates bound ficolin-2. Using the ficolin-2 binding isolate C322-17 as a model, we found 
that incubation with normal human serum led to deposition of C4b, C3b, and to MAC 
formation. No inhibition of complement deposition was observed when a C1q inhibitor 
was added, while partial inhibition was observed when ficolin-2 or factor D inhibitors 
were used separately. Combining the inhibitors against ficolin-2 and factor D led to 
virtually complete inhibition of complement deposition and protection against direct 
bacterial killing. These results demonstrate that ficolin-2 may play an important role in 
innate immune protection against EAEC when an appropriate ligand is exposed, but 
many EAEC strains evade lectin pathway recognition and may, therefore, circumvent 
this strategy of innate host immune protection.
Keywords: enteroaggregative Escherichia coli, complement, lectin pathway, ficolin-2, serum resistance
inTrODUcTiOn
Enteroaggregative Escherichia coli (EAEC) belongs to the group of diarrheagenic E. coli and is an 
increasingly recognized important cause of diarrhea. EAEC is known to cause watery and often 
persistent diarrhea in adults as well as children in both industrialized and developing countries. 
Though several virulence factors are reported, great heterogeneity among EAEC strains has made 
their molecular epidemiology unclear (1–3).
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Enteroaggregative Escherichia coli infection is initiated by 
colonization of the small and large bowel mucosal surfaces by 
aggregative adherence. This is followed by biofilm formation, 
induction of an inflammatory response, and release of toxins 
(1). The precise mechanisms of pathogenesis are still not fully 
understood, but a combination of several factors such as adhesins 
and toxins are described to contribute to disease (4, 5). However, 
none of these factors are conserved in all EAEC strains and a 
number of similar factors are found in other E. coli pathotypes, 
suggesting that EAEC pathogenesis does not depend on one 
particular protein, but is probably based on a combination of 
several virulence factors (2, 4).
Enteroaggregative Escherichia coli strains can be recovered 
from stool samples of apparently healthy individuals and 
despite studies finding strains associated with diarrhea, some 
studies have failed to show significant association between 
EAEC and disease (6–8). This suggests that host factors are 
involved in manifestations of gastrointestinal disease and fur ther 
investigations could be crucial for the understanding of EAEC 
pathogenesis.
The complement system is a complex surveillance system 
involved in innate immune protection against pathogens. It faci­
litates opsonophagocytosis of pathogens, induces inflammatory 
responses, and can lead to bacterial lysis upon activation. Acti­
vation can occur via three pathways: the lectin, the classical, and 
the alternative pathway. The complement system is primarily 
regarded to be of importance for systemic immune protection. 
But, also local production of complement components is recog­
nized as being important as exudation of complement from 
the circulation during inflammation appears to be important for 
local innate immune protection (9).
In the lectin pathway, mannose­binding lectin (MBL) and 
ficolin­1, ­2 and ­3 are pattern­recognition molecules (PRMs) 
involved in initiation of complement activation (10). Recently, 
two other molecules collectin­10 (CL­10 or CL­L1) and collec­
tin­11 (CL­11 or CL­K1) have to some degree been shown to 
mediate complement activation (11, 12). They interact with 
pathogen­associated molecular patterns on the surface of micro­
bial pathogens and upon recognition activate the lectin pathway 
with help from lectin pathway­associated serine proteases 
termed MASPs (13). The MASPs cleave C4 and C2 leading to 
the formation of the C3 convertase (C4b2a). The C3 convertase 
cleaves C3 into anaphylatoxin C3a and the strong opsonizing 
factor C3b. Activation through the classical pathway depends 
on antibody–antigen recognition, which then binds the PRM 
C1q and leads to cleavage of C4 and C2 by associated proteases 
C1r/C1s and to deposition of C3b. The alternative pathway is 
activated spontaneously by hydrolysis of C3, this allows binding 
of the factor B, which is then cleaved by factor D, forming the C3 
convertase of the alternative pathway (C3bBb). The alternative 
pathway works like an amplification loop for C3b formation 
and as C3b level rises the C5 convertase is formed (C4b2aC3b/
C3bBb3b) initiating formation of the terminal lytic C5b­9 mem­
brane attack complex (MAC) (14).
The involvement of complement in EAEC pathogenesis 
is unresolved, and though it has previously been shown that 
ficolin­2 was able to recognize EAEC (15) the importance of 
the lectin pathway is yet unknown. Thus, we hypothesized that 
the lectin pathway molecules MBL, ficolin­1, ­2, and ­3 could be 
involved in recognition and thus complement dependent protec­
tion of EAEC bacteria.
MaTerials anD MeThODs
Bacterial strains
Four prototype EAEC strains, producing aggregative adherence 
fimbriae (AAF) I–IV, were investigated for binding of lectin 
pathway recognition molecules MBL, ficolin­1, ficolin­2, and 
ficolin­3. The strains have been described previously (16). 
In addition, 56 EAEC strains isolated from stool samples 
of Danish adults suffering from diarrhea, at the diagnostic 
laboratory at Statens Serum Institut, were randomly selected. 
Stock cultures were frozen at −80°C in Luria­Bertani broth 
(LB, Sigma­Aldrich) containing 10% (vol/vol) glycerol. Bacteria 
were cultivated in Dulbecco’s modified eagle medium containing 
4.5 g/l d­Glucose (DMEM­HG, Gibco™) overnight with shak­
ing at 37°C until reaching an optical density (OD600 nm) of 1.8, 
corresponding to a bacterial concentration of approximately 
5 × 108 cells/ml.
Proteins
Expression and purification of recombinant proteins was per­
formed as previously described (17). Briefly, MBL and ficolin­1, ­2, 
and ­3 were expressed in CHO­DG44 cells cultivated in RPMI 
1640 medium (Sigma­Aldrich) supplemented with 10% fetal 
calf serum (FCS), 100 U/ml penicillin, 0.1 mg/ml streptomycin, 
2 mM l­glutamine, and 200 nM methotrexate.
consumption assay
We screened four prototypic EAEC strains for binding of 
recombinant proteins, and 56 clinical EAEC isolates for bind­
ing of serum ficolin­2. The overnight bacterial cultures were 
centrifuged at 5,000 ×  g for 5  min and washed three times in 
phosphate­buffered saline (PBS, 137  mM NaCl, 2.7  mM KCl, 
2 mM KH2PO4, and 8.1 mM Na2HPO4, pH 7.4). The cell pellet was 
resuspended in Barbital­Tween buffer (Barb­T, 5  mM barbital 
sodium, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 0.05% Tween 
20, pH 7.5) [barbital buffer previously used by Rosbjerg et  al. 
(18); Hummelshøj et al. (19)] and incubated with 10% normal 
human serum (NHS) pool originating from four healthy donors, 
for 1 h at 4°C, or in­house recombinant proteins for 2 h at 37°C, 
end­over­end. Recombinant proteins were used in the follow­
ing concentrations: recombinant ficolin­1 (rficolin­1) 2 µg/ml, 
rficolin­2 0.5 µg/ml, rficolin­3 0.5 µg/ml, and recombinant MBL 
(rMBL) 0.5 µg/ml. After centrifugation (5,000 × g, 5 min) the 
supernatant was transferred to quantification assays (described 
below) where the level of consumption was evaluated by compar­
ing the amount of remaining protein in the supernatant with a 
control sample containing no bacteria. Serum ficolin­2 screen­
ings were performed using N­Acetyl­d­glucosamine­Agarose 
(GlcNAc) beads (Sigma­Aldrich) as a positive binding control 
matrix.
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elisa—Determination of Unbound  
Protein Fraction
Maxisorp polystyrene microtiter plates (Thermo Scientific) 
were coated with 5 µg/ml acetylated bovine serum albumin or 
10 µg/ml mannan in PBS, overnight at 4°C. Plates were washed 
and blocked in Barb­T before adding the supernatants (from 
the consumption assay) in serial dilutions and incubating over­
night at 4°C. Plates were washed in Barb­T, and detection was 
performed using the following primary monoclonal antibodies 
(mAb) in a concentration of 2  µg/ml at 20°C: anti­ficolin­1 
mAb (HP9039, Hycult biotech), anti­ficolin­2 mAb clone 
FCN219 (20), anti­ficolin­3 clone FCN334 (21), and HYB­
131­11 (Bioporto Diagnostics) for MBL detection. Plates were 
incubated 2 h at room temperature, shaking. Plates were washed 
and HRP­conjugated rabbit anti­mouse polyclonal antibody 
(P0260, Dako) (1:1,500) was added for 45 min at room tempera­
ture, shaking. Plates were thoroughly washed with Barb­T and 
subsequently developed for 20 min with tetramethylbenzidine 
One (TMB ONE, Kem­En­Tec Diagnostics). The reaction was 
stopped with 0.2 M sulfuric acid (H2SO4) and OD was measured 
at 450 nm.
Western Blot—Detection  
of Bound Proteins
The bacterial cell pellets (from the consumption assay) were 
washed thoroughly in Barb­T and analyzed by western blotting. 
Bacteria were lysed with LDS sample buffer (Invitrogen) and 
the content was run on a 4–12% bis­Tris polyacrylamide gel 
(Invitrogen). Rficolin­2 (0.25 µg) was used as a loading control. 
The separated proteins were blotted onto polyvinylidene difluoride 
membranes (GE Healthcare) and the membranes were probed 
with 0.5 µg/ml anti­ficolin­1 mAb FCN106 (cross reacting with 
ficolin­2) overnight at 4°C (22). After washing, the membranes 
were incubated with rabbit anti­mouse­HRP (1:10,000) (P0260, 
Dako) for 1 h at room temperature, shaking. Membranes were 
developed using SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Scientific).
Flow cytometry—Detection  
of complement activation
Prior to assessing binding and activation with flow cytometry, 
strain C322­17 was fixed in formalin. An overnight culture of 
C322­17 was washed in PBS and the concentration was deter­
mined by a colony­forming unit (CFU) count. Bacteria were fixed 
in 4% formalin for 40 min, washed in PBS, and resuspended in 
50% ethanol. The stock was kept at −80°C until use.
10% NHS diluted in Barbital buffer containing 1% heat­
inactivated FCS (Barb­FCS) were combined with the following 
inhibitors in a concentration of 5 µg/ml: ficolin­2 inhibitory mAb 
FCN212 (18), anti­factor D inhibitory mAb clone 31A9 (anti­FD, 
a kind gift from Genentech), C1q inhibitory mAb clone 85 (C1q­
85, Sanquin), and mock inhibitor mouse IgG1 (BD Biosciences). 
Besides, ethylene diamine tetraacetic acid (EDTA) 10  mM 
(324503, Calbiochem, Merck) was applied. 5 × 107 fixed cells/ml 
were added for 30 min at 37°C. Bacteria were washed in Barb­FCS 
and spun down at 5,000 × g for 5 min at 4°C. Deposition of C4b, 
C3b, and C5b­9 were measured using biotinylated anti­C4c pAb 
(A0065, Dako), biotinylated anti­C3c pAb (A0062, Dako) and 
biotinylated anti­MAC mAb clone aE11 (23). Anti­ficolin­2 mAb 
FCN219 (20) was used to detect ficolin­2. Primary antibodies 
were applied in a concentration of 5 µg/ml for 30 min at 4°C. The 
specificity of the primary antibodies were verified using a bioti­
nylated rabbit IgG (Rb IgG, 10500C, Invitrogen) or biotinylated 
mouse IgG2 (mIgG2a, 553455, BD Pharmingen) isotype control. 
After washing, FITC­conjugated streptavidin (Strep­FITC, 
S3762, Sigma­Aldrich) were added for 30 min at 4°C. The samples 
were washed and the levels of bacterial­bound C3, C4, and MAC 
were measured by flow cytometry using Gallios Flow Cytometer 
(Beckman­Coulter) and data were analyzed using Kaluza 1.2 
software (Beckman­Coulter).
Microscopy
Ficolin­2 binding in the presence and absence of the ficolin­2 
inhibitor FCN212 was assessed by microscopy. The residual 
EAEC cells from flow cytometry was placed on slides by cyto­
spin (centrifugation for 5  min at 300 ×  g) and mounted with 
ProLong Diamond Antifade Mountant (P36965, Life Technolo­
gies). Microscopy was performed using a Zeiss Axio Observer 
through a X63/1.40 oil DIC Plan­Apochromat objective. Imaging 
conditions were kept constant when acquiring images to be 
compared.
eaec serum resistance
An overnight bacterial culture of C322­17 was diluted to an 
OD = 0.5 at 600 nm in PBS. 10% NHS were incubated in buffer 
containing the following inhibitors: FCN212 (5 µg/ml), anti­FD 
(5  µg/ml), C1q­85 (5  µg/ml) or mock inhibitor mAb Ciona 
(a mAb raised against an MBL homolog in Ciona intestinalis). 
In addition, we used a specific peptide inhibitor of C3 activa­
tion, compstatin (CP40, 6 µM, a kind gift from professor John 
Lambris, Philadelphia, PA, USA), and C5 inhibitor eculizumab 
(50 µg/ml, Soliris, Alexion Pharmaceuticals). Heat­inactivated 
NHS (IHS) (56°C, 30 min) was included as a negative control 
of complement activation. The baseline consisted of bacteria 
incubated only with buffer to assess the number of viable cells 
in the initial inoculum.
All tubes were preincubated at 37°C for 30 min to let the 
inhibitors work and to start the test approximately at human 
blood temperature. Then, 20 µl of the inoculum was added to 
each tube and the sample was homogenized. The samples were 
incubated at 37°C and 20 µl was spotted in a serial dilution of 
10−1 to 10−6 on LB agar plates and incubated at 37°C overnight 
before CFU was assessed. The control sample with viable 
cells of the initial inoculum was diluted and plated at 0 min 
incubation.
statistics
Statistical analyses were performed using GraphPad Prism 7 
(GraphPad Software, USA). The results represent the means ± SD 
of three independent experiments. For comparisons, we used 
an unpaired Student’s t­test (p-values: ns p >  0.05; *p ≤  0.05; 
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).
FigUre 1 | Consumption of recombinant MBL (rMBL), rficolin-1, -2, and -3 by prototypic EAEC strains. EAEC prototype strains JM221, 042, C1010-00,  
and 55989 were incubated with (a) rMBL (0.5 µg/ml), (B) rficolin-1 (2.0 µg/ml), (c) rficolin-2 (0.5 µg/ml), or (D) rficolin-3 (0.5 µg/ml) and the unbound protein  
fraction was transferred to wells coated with mannan or acetylated bovine serum albumin and detected by specific mAb against mannose-binding  
lectin (MBL), ficolin-1, -2, or -3.
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resUlTs
Binding of rMBl and Ficolins  
to Prototypic eaec strains
Four prototypic EAEC strains were screened in a consump­
tion assay for binding of rMBL, rficolin­1, ­2, and ­3. Neither 
rficolin­1 nor rficolin­3 appeared to bind to any of the strains 
(Figures 1B,D), whereas rMBL showed binding to two of the 
strains (JM221 and 042) (Figure  1A). The strongest binding, 
however, was observed for rficolin­2, which displayed high 
binding to two strains (55989 and C1010­00) and to a lesser 
degree to strain 042 (Figure 1C). We confirmed the binding by 
performing a Western blot on the eluates from the consumption 
assay (data not shown).
We found that rficolin­2 displayed highest binding to the 
four prototypic EAEC strains and, therefore, decided to examine 
ficolin­2 binding to 56 clinical EAEC isolates.
Binding of serum Ficolin-2 to 56  
clinical eaec isolates
56 clinical EAEC isolates obtained from adult patients suffer­
ing from EAEC­related diarrhea were screened for binding of 
serum ficolin­2 and the unbound fraction of serum ficolin­2 
was measured. Five (8.9%) of the 56 isolates appeared to bind 
serum ficolin­2 and especially one isolate, C322­17, showed 
very strong binding (Figure 2). We furthermore verified that 
serum ficolin­2 was bound to isolate C322­17 by performing 
a Western blot on the bacterial pellet for C322­17 and two 
isolates that were negative for ficolin­2 binding according to 
the ELISA. The Western blot showed strong monomeric and 
oligomeric ficolin­2 structures to be associated with C322­17. 
The two isolates, E3­1065539 and H57553, which were nega­
tive for ficolin­2 binding in the ELISA displayed low levels of 
oligomeric ficolin­2 binding, but no monomeric bands were 
observed (Figure 3).
Since isolate C322­17 displayed high binding of ficolin­2, we 
decided to use this isolate as a model for further investigation of 
EAEC­associated complement binding and activation.
calcium Dependency of Ficolin-2 Binding
We examined whether ficolin­2 binding to isolate C322­17 was 
calcium dependent by pre­incubating NHS with 10 mM EDTA. 
Figure  4 shows the mean fluorescence intensities (MFI) when 
detecting ficolin­2 binding in flow cytometry. Ficolin­2 bind­
ing was not reduced by EDTA providing evidence that that the 
binding was calcium independent. In fact, it seemed that EDTA 
FigUre 2 | Consumption of serum ficolin-2 by 56 clinical Enteroaggregative Escherichia coli (EAEC) isolates. 56 clinical EAEC isolates and a control containing 
GlcNAc beads were incubated with 10% normal human serum and the unbound protein fraction was transferred to ELISA plates coated with acetylated bovine 
serum albumin, in twofold serial dilutions. Specific mAb were used to detect ficolin-2. Boxes show isolates binding ficolin-2 and * marks isolate C322-17  
showing high binding of ficolin-2.
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enhanced binding of ficolin­2, perhaps due to elimination of 
other calcium­dependent binding partners.
complement activation by Ficolin-2 
Through the lectin Pathway
The contribution of ficolin­2 to lectin pathway complement 
activation was assessed by introducing FCN212, a ficolin­2 
inhibitory mAb. Figures  5A,B shows inhibition of ficolin­2 
binding to the bacterial strain C322­17 in flow cytometry 
and fluorescence microscopy, respectively, when applying 
the inhibitor. Both techniques showed that the binding was 
reduced by the employed ficolin­2 inhibitor. In flow cyto­
metry, the inhibition was significantly reduced both when 
comparing to 10% NHS and to a mock ficolin­2 inhibitor 
(p < 0.0001).
The effect of ficolin­2 binding on complement activation 
was examined by looking at the deposition of C4b, C3b, and 
FigUre 4 | Ficolin-2 binding is independent of calcium. Isolate C322-17  
was incubated with 10% normal human serum (NHS) in Barb-fetal calf serum 
(FCS), and 10% NHS in Barb-FCS + 10 mM ethylene diamine tetraacetic 
acid (EDTA). Binding of ficolin-2 was detected with specific biotinylated mAb 
against ficolin-2 and FITC-conjugated Streptavidin. Complement deposition 
was measured by flow cytometry and expressed as mean fluorescence 
intensity (MFI). Results represent the means of three independent 
experiments ± SD.
FigUre 3 | Western blot detection of bound serum ficolin-2 to isolate 
C322-17. Isolates C322-17 (high binding), E3-1065539 (low binding), and 
H57553 (low binding) was incubated with 10% normal human serum and  
the eluates were separated by SDS PAGE and detected by western blot. 
0.25 µg rficolin-2 was added as a positive control and specific mAb  
was used to detect ficolin-2.
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MAC in the presence and absence of the ficolin­2 inhibitor. 
C4b deposition was significantly reduced by the inhibitor when 
comparing to both 10% NHS and the mock inhibitor (p = 0.0008 
and 0.0026, respectively). The same tendencies were observed 
for MAC deposition when comparing to 10% NHS and the 
mock inhibitor (p  =  0.0189 and 0.0134, respectively), sug­
gesting an involvement of ficolin­2 and the lectin pathway in 
complement activation (Figures 6A,C). We observed a small 
significant reduction in C3b deposition when comparing to 
10% NHS (p = 0.0495), but were unable to detect a significant 
reduction when comparing to the mock inhibitor (p = 0.0964), 
but overall the tendency followed that of C4b and MAC 
(Figure 6B). We also looked at MBL binding to see if this was 
involved in activation via the lectin pathway, but MBL did not 
bind to C322­17 and thus does not contribute to activation 
(data not shown).
The classical Pathway Does not show 
involvement in complement activation
Since ficolin­2 only seemed to be partially involved in comple­
ment activation, we investigated whether the remaining activity 
was initiated via the classical pathway. When introducing an 
inhibitor of C1q, we saw no significant reduction in the deposi­
tion of C4b, C3b, or MAC (p >  0.05) (Figures 7A–C, respec­
tively) and, therefore, the classical pathway does not appear to 
be involved in the remaining complement activity.
The alternative Pathway contributes  
to complement activation
Next, we tested the involvement of the alternative pathway by 
applying an inhibitory antibody against factor D before detect­
ing C3b and MAC deposition (Figure  8). We were unable to 
detect a significant reduction in C3b levels when introducing the 
factor D inhibitor alone. However, when combining the factor D 
inhibitor with the ficolin­2 inhibitor, we observed a significant 
reduction in C3b deposition when comparing both to 10% NHS 
and to a sample where the ficolin­2 inhibitor was exchanged 
with a mock inhibitor (p =  0.0057 and 0.0002, respectively) 
(Figure 8A). The deposition of MAC was highly reduced by the 
factor D inhibitor alone (10% NHS p = 0.0058 and mock inhibi­
tor p < 0.0001) and adding the ficolin­2 inhibitor led to further 
reductions when comparing to the mock inhibitor (p = 0.0169) 
(Figure 8B).
These data suggest that both the lectin pathway and the 
alternative pathway are important in activation of complement 
on EAEC strain C322­17 and emphasize the importance of the 
alternative pathway in generation of MAC.
Ficolin-2 and Factor D are involved  
in serum-Mediated eaec Killing
To further investigate the involvement of ficolin­2 and the 
alternative pathway on bacterial clearance, we performed a 
serum resistance assay where bacteria were mixed with 10% 
NHS and the inhibitors of ficolin­2, factor D and C1q, as well 
as the C3­targeted complement inhibitor, compstatin, and 
the terminal complement inhibitor eculizumab that prevents 
MAC formation. We assessed the change in CFU/ml between 
10% NHS and the different parameters. There was a significant 
reduction when bacteria were grown in 10% NHS compared to 
the baseline (No NHS) (p =  0.0046). Heat­inactivated human 
serum (IHS) was applied as a control of complement activity 
and did not only lead to rescue of bacterial growth, but could be 
interpreted to function as a growth medium for the bacteria. The 
C1q inhibitor did not rescue the bacteria (p = 0.6904), suggest­
ing no involvement from the classical pathway in the observed 
serum­mediated killing. The ficolin­2 inhibitor and the factor D 
inhibitor each led to significant bacterial rescue (p = 0.0029 and 
FigUre 6 | Inhibitory effects of a ficolin-2 inhibitor on C4b, C3b, and membrane attack complex (MAC) deposition. 10% normal human serum (NHS) was  
combined with ficolin-2 inhibitor FCN212 (5 µg/ml) and incubated with isolate C322-17. Detection was performed with specific biotinylated monoclonal antibodies 
against (a) C4b, (B) C3b, and (c) MAC, followed by FITC-conjugated Streptavidin. Complement deposition was measured by flow cytometry and expressed  
as mean fluorescence intensity (MFI). Results represent the means of three independent experiments ± SD, ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
(unpaired Student’s t-test).
FigUre 5 | Inhibitory effects of ficolin-2 inhibitor on ficolin-2 binding. 10% normal human serum (NHS) was combined with ficolin-2 inhibitor FCN212 (5 µg/ml)  
and incubated with isolate C322-17. Detection was performed with specific biotinylated monoclonal antibodies against ficolin-2, followed by FITC-conjugated 
Streptavidin. (a) Ficolin-2 deposition was measured by flow cytometry and expressed as mean fluorescence intensity (MFI). (B) Residual EAEC cells from flow 
cytometry was placed on slides by cytospin and examined by bright field (BF) and fluorescent microscopy (FITC). Results represent the means of three  
independent experiments ± SD, ****p ≤ 0.0001 (unpaired Student’s t-test).
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0.0130, respectively), suggesting involvement of both the lectin 
and alternative pathway in serum­mediated killing. Combining 
the two inhibitors did not appear to further increase the rescue. 
Targeting C3 and MAC with inhibitors also led to significant 
rescue of bacterial growth (p = 0.0107 and 0.0038, respectively) 
(Figure 9).
DiscUssiOn
Enteroaggregative Escherichia coli (EAEC) is a well­known 
diar rheagenic pathogen, causing acute and persistent diarrhea 
in children and adults worldwide. However, the molecular epi­
demiology of EAEC still remains unclear and several studies 
have recovered EAEC from stool samples of apparently healthy 
individuals suggesting the involvement of host factors (2).
The lectin pathway of the complement system relies on 
PRMs to assist in the clearance of microbial intruders. Ficolins 
are a family of PRMs belonging to the lectin pathway. They 
bind structures such as N­acetyl­glucosamine (GlcNAc), 
N­acetyl­galactosamine (GalNAc) and acetylated compounds 
on target cells (24). Although complement proteins are generally 
considered in the systemic compartment, recent studies show 
FigUre 8 | Inhibitory effects of a factor D inhibitor on C3b, and membrane attack complex (MAC) deposition. 10% normal human serum (NHS) was  
combined with a factor D inhibitor (5 µg/ml) and incubated with isolate C322-17. Detection was done with specific biotinylated monoclonal antibodies  
against (a) C3b and (B) MAC, followed by FITC-conjugated Streptavidin. Complement deposition was measured by flow cytometry and expressed as  
mean fluorescence intensity (MFI). Results represent the means of three independent experiments ± SD, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 
(unpaired Student’s t-test).
FigUre 7 | Inhibitory effects of a C1q inhibitor on C4b, C3b, and membrane attack complex (MAC) deposition. 10% normal human serum (NHS) was combined 
with C1q inhibitor C1q-85 (5 µg/ml) and incubated with isolate C322-17. Detection was done with specific biotinylated monoclonal antibodies against (a) C4b,  
(B) C3b, and (c) MAC, followed by FITC-conjugated Streptavidin. Complement deposition was measured by flow cytometry and expressed as mean fluorescence 
intensity (MFI). Results represent the means of three independent experiments ± SD. No significant differences were detected between the C1q inhibitor  
and the mock inhibitor, ns p > 0.05 (unpaired Student’s t-test).
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production and secretion of complement components in human 
immune cells, as well as endothelial and epithelial cells (9). This 
makes the study of interactions between rare or non­systemic 
pathogens and complement highly relevant and could potentially 
give a better understanding of host defense systems, as well as 
bacterial pathogenesis.
In this study, we assessed the involvement of the lectin comple­
ment pathway on 56 EAEC strains isolated from patients suffer­
ing from EAEC­related diarrhea. First, we applied a consumption 
assay to screen the binding of rMBL and ficolins to prototypic 
EAEC strains in an ELISA setup. We found that rficolin­2 pre­
sented with the highest binding capacities for the prototype 
EAEC strains, showing strong binding to prototype strains 55989 
and C1010­00, and to some degree to prototype 042. In a pre­
vious study no binding of ficolin­2 to prototype strain E. coli 042 
was detected, but they were using NHS (serum protein) and in 
a different E. coli growth medium (15). Using a different growth 
medium for EAEC could potentially change the gene expres­
sion of the strain and lead to changes in surface presentation. 
Biofilm formation in some EAEC strains have shown to increase 
FigUre 9 | Inhibitors of ficolin-2 and factor D reduce serum-mediated 
enteroaggregative Escherichia coli (EAEC) killing. Bacterial growth in normal 
human serum (NHS) measured by colony-forming unit (CFU)/ml. EAEC isolate 
C322-17 was incubated with 10% NHS in combination with complement 
inhibitors of ficolin-2, factor D, C1q, C3 (compstatin), and C5 (eculizumab).  
A baseline (No NHS) was established from an overnight culture under  
normal growth conditions without the presence of NHS or inhibitors. Results 
represent the means of three independent experiments ± SD. All conditions 
are compared to 10% NHS, ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01 (unpaired 
Student’s t-test).
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significantly when using a high glucose containing medium as 
compared to regular LB (25). This emphasizes the importance of 
the methodology employed when studying bacterial interaction 
with host factors.
Based on our initial screenings, we focused on the PRM 
ficolin­2. Previous reports have described binding of ficolin­2 
to Gram­positive bacteria, such as group B streptococci, S. pneu-
moniae, S. pyogenes, and capsulated S. aureus (26–28), but very 
few studies have described binding of ficolin­2 to Gram­negative 
bacteria. A study by Sahagún­Ruiz et  al. explored the binding 
capacity of serum ficolin­2 and ficolin­3 to Gram­negative 
bacteria including four EAEC strains. They found that ficolin­2 
and ficolin­3 recognized one EAEC strain (serotype O71), 
but not the other three. By testing binding to another EAEC 
serotype O71 they concluded that binding was not related to 
the bacterial LPS type (15), but did not determine the specific 
binding factor.
The binding capacity of the 56 clinical EAEC isolates was 
screened by incubating bacteria with 10% NHS. Ficolin­2 bind­
ing was only detected in five of the 56 EAEC isolates (8.9%). 
Complement evasion strategies are numerous and include 
mimicking or recruitment of complement regulators, inhibition 
of complement proteins, and enzymatic degradation leading 
to inactivation (29). Both Gram­positive and Gram­negative 
bacteria are capable of evading complement by recruitment of 
complement regulators, such as factor H and C4b­binding pro­
tein (C4BP) (30). The E. coli K1, causing neonatal meningitis, 
utilizes the outer membrane protein A (OmpA) as protection 
against complement­mediated killing, and serum resistance 
was correlated with the binding of C4bP to OmpA (31, 32). 
Immune evasion has also been reported for EAEC by cleavage of 
complement proteins by Pic, which is a serine protease present 
in approximately 50% of clinical EAEC isolates (4, 5, 33, 34). 
In a study by Abreu et  al., they showed that Pic significantly 
reduced complement activation by cleavage of C3, C3b, C4, 
and C2, thereby affecting all three complement pathways (35). 
EAEC is known to cause persistent diarrhea, most likely due to 
the formation of a resilient biofilm. A study from 2013 showed 
that biofilm formation worked as an efficient way of evading 
complement detection (36) and could potentially be a way for 
EAEC to avoid complement. As part of the present study, we 
investigated whether ficolin­2 binding could be related to the five 
EAEC characteristic AAF (I–V). By PCR, we characterized the 
presence of AAFs in the 56 clinical EAEC strains, but we were 
unable to find a link between binding of ficolin­2 and the pres­
ence of a specific AAF, the strains that bound ficolin­2 harbored 
different AAFs (data not shown). We hypothesize that some 
bacterial strains are able to change their surface composition 
in order to avoid ficolin­2 binding, thus escaping the initiating 
effect of complement.
It is important to mention that we did see a difference in detec­
tion of ficolin­2 binding when comparing ELISA with western 
blot. Two of the strains reported negative for binding in the 
ELISA, were run on a western blot where we were able to detect 
low levels of oligomeric binding. This should be tested further to 
determine the sensitivity of the ELISA.
Before assessing the complement activation potential of 
EAEC, we determined whether ficolin­2 binding was calcium 
dependent. X­ray crystallographic analysis has revealed 
four different binding sites in the fibrinogen­like domain of 
ficolin­2, enabling binding to a wide variety of ligands (24). 
While some of these binding sites require the presence of 
calcium, others can bind calcium independently (10). Using 
isolate C322­17 as a model for high level ficolin­2 binding, we 
could show that ficolin­2 binding to the bacteria was calcium­ 
independent.
We next showed that ficolin­2 binding to EAEC can lead 
to activation of complement. The activation could be partially 
inhibited by a ficolin­2­specific inhibitor. Furthermore, activa­
tion was independent of the classical pathway, thereby confirm­
ing the involvement of the lectin pathway of complement. We 
also show that the alternative pathway contributes to activation 
and that the amplification loop contributes to a high produc­
tion of C3b, possibly explaining the need to introduce both a 
ficolin­2 inhibitor and a factor D inhibitor to see a decreasing 
effect on C3b levels. This observation is compatible with previous 
studies on fungi showing the importance of alternative path way 
amplification on lectin pathway­initiated activation (18).
Finally, we show that ficolin­2 and factor D are involved 
in serum­mediated killing of EAEC and that this killing is 
com pletely dependent on the formation of the MAC complex. 
Although EAEC is not common in sepsis infections, there have 
been reports of EAEC­induced bacteremia (37, 38), and this 
could be due to lack of complement dependent systemic control 
of the infection.
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cOnclUsiOn
This study shows for the first time a crucial influence of ficolin­2 
in the control of some strains of EAEC bacteria, but it also shows 
that only a fraction of the strains indeed binds ficolin­2 by mecha­
nisms that remain to be elucidated. This suggests that many EAEC 
strains may evade ficolin­2 and probably other innate immune 
recognition mechanisms in their pathogenic survival strategies.
aUThOr cOnTriBUTiOns
CS: study design, experimental work, data interpretation, drafting 
the article, and final approval. AR, KK, and PG: study design, data 
interpretation, critical revision of the article, and final approval. BJ: 
collection of clinical strains used in the study and final approval.
acKnOWleDgMenTs
The authors wish to thank their colleagues from the Department 
of Clinical Immunology at Rigshospitalet. The authors acknowl­
edge the excellent technical assistance from Ms. Jytte Bryde 
Clausen. The authors also wish to thank Rie Jønsson and Susanne 
Jespersen from Statens Serum Institut for assistance in handling 
and characterizing the EAEC strains.
FUnDing
This work was supported by grants from the Danish Research 
Foundation of Independent Research (DFF­6110­00489), the 
Sven Andersen Research Foundation, the Novo Nordisk Research 
Foundation, and the Research Foundation at Rigshospitalet.
reFerences
1. Hebbelstrup Jensen B, Olsen KEP, Struve C, Krogfelt KA, Petersen AM. 
Epidemiology and clinical manifestations of enteroaggregative Escherichia 
coli. Clin Microbiol Rev (2014) 27:614–30. doi:10.1128/CMR.00112­13 
2. Okeke IN, Nataro JP. Enteroaggregative Escherichia coli. Lancet Infect Dis 
(2001) 1:304–13. doi:10.1016/S1473­3099(01)00144­X 
3. Kaper JB, Nataro JP, Mobley HLT. Pathogenic Escherichia coli. Nat Rev 
Microbiol (2004) 2:123–40. doi:10.1038/nrmicro818 
4. Boisen N, Scheutz F, Rasko DA, Redman JC, Persson S, Simon J, et al. Genomic 
characterization of enteroaggregative Escherichia coli from children in Mali. 
J Infect Dis (2012) 205:431–44. doi:10.1093/infdis/jir757 
5. Hebbelstrup Jensen B, Poulsen A, Hebbelstrup Rye Rasmussen S, Struve C, 
Engberg JH, Friis­Møller A, et al. Genetic virulence profile of enteroaggre­
gative Escherichia coli strains isolated from Danish children with either acute 
or persistent diarrhea. Front Cell Infect Microbiol (2017) 7:230. doi:10.3389/
fcimb.2017.00230 
6. Gomes TAT, Blake PA, Trabulsi LR. Prevalence of Escherichia coli strains 
with localized, diffuse, and aggregative adherence to hela cells in infants with 
diarrhea and matched controls. J Clin Microbiol (1989) 27:266–9. 
7. Mathewson JJ, Johnson PC, DuPont HL, Satterwhite TK, Winsor DK. 
Pathogenicity of enteroadherent Escherichia coli in adult volunteers. J Infect 
Dis (1986) 154:524–7. doi:10.1093/infdis/154.3.524 
8. Nataro JP, Yikang D, Cookson S, Cravioto A, Savarino SJ, Guers LD, et  al. 
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in 
volunteers. J Infect Dis (1995) 171:465–8. doi:10.1093/infdis/171.2.465 
9. Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of comple­
ment components by cells of the immune system. Clin Exp Immunol (2017) 
188:183–94. doi:10.1111/cei.12952 
10. Garred P, Genster N, Pilely K, Bayarri­Olmos R, Rosbjerg A, Ma YJ, et  al. 
A journey through the lectin pathway of complement­MBL and beyond. 
Immunol Rev (2016) 274:74–97. doi:10.1111/imr.12468 
11. Axelgaard E, Jensen L, Dyrlund TF, Nielsen HJ, Enghild JJ, Thiel S, et  al. 
Investigations on collectin liver 1. J Biol Chem (2013) 288:23407–20. 
doi:10.1074/jbc.M113.492603 
12. Ma YJ, Skjoedt MO, Garred P. Collectin­11/MASP complex formation 
triggers activation of the lectin complement pathway – the fifth lectin 
pathway initiation complex. J Innate Immun (2013) 5:242–50. doi:10.1159/ 
000345356 
13. Dobó J, Pál G, Cervenak L, Gál P. The emerging roles of mannose­binding 
lectin­associated serine proteases (MASPs) in the lectin pathway of comple­
ment and beyond. Immunol Rev (2016) 274:98–111. doi:10.1111/imr.12460 
14. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system 
for immune surveillance and homeostasis. Nat Immunol (2010) 11:785–97. 
doi:10.1038/ni.1923 
15. Sahagún­Ruiz A, Breda LC, Valencia MM, Elias WP, Munthe­Fog L, Garred P, 
et al. Studies of the binding of ficolin­2 and ficolin­3 from the complement lec­
tin pathway to Leptospira biflexa, Pasteurella pneumotropica and diarrheagenic 
Escherichia coli. Immunobiology (2015) 220:1177–85. doi:10.1016/j.imbio. 
2015.06.001 
16. Jønsson R, Struve C, Boisen N, Valentina Mateiu R, Santiago AE, Jenssen H, 
et  al. Novel aggregative adherence fimbria variant of enteroaggregative 
Escherichia coli. Infect Immun (2015) 83:1396–405. doi:10.1128/IAI.02820­14 
17. Hummelshøj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. 
Molecular organization of human ficolin­2. Mol Immunol (2007) 44:401–11. 
doi:10.1016/j.molimm.2006.02.023 
18. Rosbjerg A, Genster N, Pilely K, Skjoedt MO, Stahl GL, Garred P. Com­
plementary roles of the classical and lectin complement pathways in the defense 
against Aspergillus fumigatus. Front Immunol (2016) 7:473. doi:10.3389/ 
fimmu.2016.00473 
19. Hummelshøj T, Ma YJ, Munthe­Fog L, Bjarnsholt T, Moser C, Skjoedt MO, 
et al. The interaction pattern of murine serum ficolin­A with microorganisms. 
PLoS One (2012) 5:e38196. doi:10.1371/journal.pone.0038196 
20. Munthe­Fog L, Hummelshøj T, Hansen BE, Koch C, Madsen HO, Skjødt K, 
et al. The Impact of FCN2 polymorphisms and haplotypes on the ficolin­2 
serum levels. Scand J Immunol (2007) 65:383–92. doi:10.1111/j.1365­3083. 
2007.01915.x 
21. Munthe­Fog L, Hummelshøj T, Ma YJ, Hansen BE, Koch C, Madsen HO, 
et al. Characterization of a polymorphism in the coding sequence of FCN3 
resulting in a ficolin­3 (Hakata Antigen) deficiency state. Mol Immunol (2008) 
45:2660–6. doi:10.1016/j.molimm.2007.12.012 
22. Munthe­Fog L, Hummelshoj T, Honoré C, Moller ME, Skjoedt MO, 
Palsgaard I, et al. Variation in FCN1 affects biosynthesis of ficolin­1 and is 
associated with outcome of systemic inflammation. Genes Immun (2012) 
13:515–22. doi:10.1038/gene.2012.27 
23. Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing 
a neoantigen of poly(C9) detect the human terminal complement complex 
in tissue and plasma. Scand J Immunol (1985) 22:183–95. doi:10.1111/j.1365­ 
3083.1985.tb01871.x 
24. Garlatti V, Belloy N, Martin L, Lacroix M, Matsushita M, Endo Y, et  al. 
Structural insights into the innate immune recognition specificities of L­ and 
H­ficolins. EMBO J (2007) 26:623–33. doi:10.1038/sj.emboj.7601500 
25. Sheikh J, Hicks S, Dall’Agnol M, Phillips AD, Nataro JP. Roles for Fis and YafK 
in biofilm formation by enteroaggregative Escherichia Coli. Mol Microbiol 
(2001) 5:983–97. doi:10.1046/j.1365­2958.2001.02512.x 
26. Aoyagi Y, Adderson EE, Min JG, Matsushita M, Fujita T, Takahashi S, et al. 
Role of L­Ficolin/mannose­binding lectin­associated serine protease com­
plexes in the opsonophagocytosis of type III group B streptococci. J Immunol 
(2005) 174:418–25. doi:10.4049/jimmunol.174.1.418 
27. Aoyagi Y, Adderson EE, Rubens CE, Bohnsack JF, Min JG, Matsushita M, 
et al. L­Ficolin/mannose­binding lectin­associated serine protease complexes 
bind to group B streptococci primarily through N­acetylneuraminic acid of 
capsular polysaccharide and activate the complement pathway. Infect Immun 
(2008) 76:179–88. doi:10.1128/IAI.00837­07 
28. Krarup A, Skov Sørensen UB, Matsushita M, Jensenius JC, Thiel S. Effect of 
capsulation of opportunistic pathogenic bacteria on binding of the pattern 
11
Adler Sørensen et al. Ficolin-2 and EAEC
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1153
recognition molecules mannan­binding lectin, L­ficolin, and H­ficolin. Infect 
Immun (2005) 73:1052–60. doi:10.1128/IAI.73.2.1052­1060.2005 
29. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human patho­
gens. Nat Rev Microbiol (2008) 6:132–42. doi:10.1038/nrmicro1824 
30. Kraiczy P, Würzner R. Complement escape of human pathogenic bacteria 
by acquisition of complement regulators. Mol Immunol (2006) 43:31–44. 
doi:10.1016/j.molimm.2005.06.016 
31. Weiser JN, Gotschlich EC. Outer membrane protein A (OmpA) contributes 
to serum resistance and pathogenicity of Escherichia coli K­1. Infect Immun 
(1991) 59:2252–8. 
32. Prasadarao NV, Blom AM, Villoutreix BO, Linsangan LC. A novel interaction 
of outer membrane protein A with C4b binding protein mediates serum 
resistance of Escherichia coli K1. J Immunol (2002) 169:6352–60. doi:10.4049/
jimmunol.169.11.6352 
33. Piva IC, Pereira AL, Ferraz LR, Silva RSN, Vieira AC, Blanco JE, et al. Virulence 
markers of enteroaggregative Escherichia Coli isolated from children and 
adults with diarrhea in Brasília, Brazil. J Clin Microbiol (2003) 41:1827–32. 
doi:10.1128/JCM.41.5.1827­1832.2003 
34. Boisen N, Ruiz­Perez F, Scheutz F, Krogfelt KA, Nataro JP. High prevalence 
of serine protease autotransporter cytotoxins among strains of enteroaggre­
gative Escherichia coli. Am J Trop Med Hyg (2009) 80:294–301. 
35. Abreu AG, Fraga TR, Granados Martinez AP, Kondo MY, Juliano MA, 
Juliano L, et  al. The serine protease pic from enteroaggregative Escherichia 
coli mediates immune evasion by the direct cleavage of complement proteins. 
J Infect Dis (2015) 212:106–15. doi:10.1093/infdis/jiv013 
36. Domenech M, Ramos­Sevillano E, García E, Moscoso M, Yuste J. Biofilm 
formation avoids complement immunity and phagocytosis of Strepto-
coccus pneumoniae. Infect Immun (2013) 81:2606–15. doi:10.1128/IAI. 
00491­13 
37. Scheutz F, Møller Nielsen E, Frimodt­Møller J, Boisen N, Morabito S, 
Tozzoli R, et  al. Characteristics of the enteroaggregative Shiga toxin/ vero­
toxin­producing Escherichia coli O104:H4 strain causing the outbreak of 
haemolytic uraemic syndrome in Germany. Euro Surveill (2011) 16:1–6. 
38. Herzog K, Engeler Dusel J, Hugentobler M, Beutin L, Sägesser G, Stephan R, 
et al. Diarrheagenic enteroaggregative Escherichia coli causing urinary tract infec­
tion and bacteremia leading to sepsis. Infection (2014) 42:441–4. doi:10.1007/ 
s15010­013­0569­x 
Conflict of Interest Statement: The authors declare that the research was con­
ducted in the absence of any commercial or financial relationships that could be 
constructed as a potential conflict of interest.
Copyright © 2018 Adler Sørensen, Rosbjerg, Hebbelstrup Jensen, Krogfelt and 
Garred. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) and the copyright owner 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
